Pancreatic Cancer Research

ResearcherAichi Medical UniversityActive in the last 2 years

Yasuhiro Kodera

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6173-7474; OpenAlex author ID A5018146056, A5054229023, A5056235121. Sources: OpenAlex.

Their work

Papers
76 (first author 1, last author 49)
Trials
0
Grants
0
Labs led
1
Collaborators
135
Papers, trials and grants by year

2011: 5 papers · 2012: none · 2013: 3 papers · 2014: 5 papers · 2015: 3 papers · 2016: 4 papers · 2017: 4 papers · 2018: 8 papers · 2019: 4 papers · 2020: 9 papers · 2021: 7 papers · 2022: 9 papers · 2023: 8 papers · 2024: 2 papers · 2025: 4 papers · 2026: 1 paper

Papers 50 of 76

  1. A Case of Pancreatic Cancer Complicated by Active Pulmonary Tuberculosis Successfully Managed through a Multidisciplinary Treatment Strategy. Last author DOI 10.70352/scrj.cr.26-0532↗
  2. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  3. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Last author DOI 10.1093/bjs/znaf049↗
  4. Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Nab-Paclitaxel-Treated Unresectable or Rec… Last author DOI 10.1097/mpa.0000000000002446↗
  5. Exploration of Lipid Mediators for Therapeutic Monitoring of Pancreatic Cancer Patients. Last author DOI 10.21873/anticanres.17520↗
  6. Genome-wide microRNA Analysis Identified miR-210-3p Over-expression in Pancreatic Cancer Tissues as a Predictor of their Local Invasiveness. Last author DOI 10.21873/anticanres.17297↗
  7. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.5946/ce.2022.278↗
  8. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreati… Co-author DOI 10.1002/ags3.12613↗
  9. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  10. Predictive impacts of peritoneal washing cytology for surgical resection-intended pancreatic cancer cases: Establishment of planned staging laparoscopy criteri… Last author DOI 10.1002/jhbp.1373↗
  11. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s10147-023-02321-1↗
  12. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  13. Intratumoral Malasseziaglobosa Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2023.04.017↗
  14. Albumin-Globulin Ratio Indicates the Survival Outcome of Pancreatic Cancer Cases Who Underwent Preoperative Treatment and Curative Surgical Resection. Last author DOI 10.1080/01635581.2023.2191384↗
  15. High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients. Last author DOI 10.21873/anticanres.16491↗
  16. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  17. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003945↗
  18. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  19. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
  20. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  21. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  22. Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation… Last author DOI 10.1245/s10434-022-12039-5↗
  23. ASO Author Reflections: Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Prolifer… Last author DOI 10.1245/s10434-022-12070-6↗
  24. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. Last author DOI 10.21873/anticanres.15882↗
  25. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Last author DOI 10.1007/s00595-020-02220-2↗
  26. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Last author DOI 10.1097/mpa.0000000000001712↗
  27. Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy. Last author DOI 10.1186/s13148-021-01165-8↗
  28. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-020-08990-w↗
  29. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  30. A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes. Last author DOI 10.21873/anticanres.15189↗
  31. C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10061502↗
  32. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  33. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preopera… Last author DOI 10.1002/jhbp.748↗
  34. Clinical impact of additional therapy for residual pancreatic cancer. Last author DOI 10.1007/s00595-019-01900-y↗
  35. Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001559↗
  36. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Last author DOI 10.1245/s10434-019-07981-w↗
  37. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-019-08047-7↗
  38. ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-019-08056-6↗
  39. Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Last author DOI 10.21873/anticanres.14138↗
  40. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13010036↗
  41. Effects of duration of initial treatment on postoperative complications in pancreatic cancer. Last author DOI 10.1002/jhbp.622↗
  42. Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. Last author DOI 10.1016/j.ejso.2019.05.019↗
  43. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. Last author DOI 10.1016/j.hpb.2019.01.012↗
  44. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Last author DOI 10.18999/nagjms.81.2.233↗
  45. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Last author DOI 10.1007/s00280-018-3554-3↗
  46. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Last author DOI 10.1038/s41598-018-28253-9↗
  47. Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001105↗
  48. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Last author DOI 10.1097/mpa.0000000000001110↗
  49. Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Last author DOI 10.1097/mpa.0000000000001186↗
  50. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1186/s12885-018-4453-z↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suguru Yamada · 55 shared papers, 2011–2023 · strength 4.50
  2. Tsutomu Fujii · 49 shared papers, 2011–2025 · strength 3.87
  3. Masamichi Hayashi · 36 shared papers, 2011–2025 · strength 3.79
  4. Mitsuro Kanda · 42 shared papers, 2011–2025 · strength 3.58
  5. Fuminori Sonohara · 25 shared papers, 2018–2025 · strength 2.61
  6. Norifumi Hattori · 14 shared papers, 2015–2025 · strength 1.70
  7. Tomohisa Otsu · 6 shared papers, 2022–2025 · strength 1.12
  8. Nobuhiko Nakagawa · 6 shared papers, 2020–2025 · strength 1.11
  9. Masaya Suenaga · 13 shared papers, 2014–2025 · strength 0.98
  10. Junpei Yamaguchi · 7 shared papers, 2018–2025 · strength 0.94
  11. Nobutake Tanaka · 7 shared papers, 2018–2023 · strength 0.93
  12. Hiroyuki Sugimoto · 21 shared papers, 2011–2017 · strength 0.93
  13. Mitsuru Tashiro · 6 shared papers, 2018–2026 · strength 0.86
  14. Sohei Satoi · 7 shared papers, 2017–2025 · strength 0.81
  15. Yukihiro Yokoyama · 6 shared papers, 2018–2024 · strength 0.74
  16. Ajay Goel · 5 shared papers, 2022–2023 · strength 0.72
  17. Tomoki Ebata · 4 shared papers, 2022–2025 · strength 0.70
  18. Tomohisa Yamamoto · 6 shared papers, 2017–2025 · strength 0.67
  19. Daniel D. Von Hoff · 4 shared papers, 2022–2023 · strength 0.55
  20. Fuyuhiko Motoi · 5 shared papers, 2017–2025 · strength 0.54
  21. Hiroki Kawashima · 5 shared papers, 2018–2024 · strength 0.53
  22. Daisuke Hashimoto · 4 shared papers, 2021–2025 · strength 0.53
  23. Masaya Yamanaka · 3 shared papers, 2021–2022 · strength 0.50
  24. So Yamaki · 4 shared papers, 2020–2025 · strength 0.48
  25. Joji Kitayama · 4 shared papers, 2020–2025 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.